[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Asia Cervical Cancer Diagnostic Market, By Test Type (Pap smear, HPV DNA and VIA), Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) & Forecast

June 2018 | | ID: A0F94200DD7EN
Renub Research

US$ 1,290.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery, E-mail Delivery (Word)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Cervical cancer diagnostic market in Asian region is growing and expected to cross over USD 1 Billion by 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. Despite declining women population, Japan has highest market share in cervical cancer test market. Whereas Indonesia is dominating in cervical cancer testing population followed by China.

Growing women population, rising sum of structured cervical cancer programs introduced by governments and international NGOs and inception of low cost VIA test are some of the major growth drivers for the growth of cervical cancer test market in the developing countries.

Renub Research report titled “Asia Cervical Cancer Diagnostic Market, By Test Type (Pap smear, HPV DNA and VIA), Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) & Forecast” provides a complete analysis of Asia Cervical Cancer Screening Market. The report provides a complete analysis of Asia Countries Cervical Cancer Test Market, Screened Population & Mortality.

By Test Types – Pap smear Screening Tests is gaining popularity in Asia, although VIA has bright future due to its lower cost characteristic.

The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests, HPV DNA Tests and VIA Tests. Pap smears and VIA tests is more popular with the developing countries such as India, China, and Indonesia.

By Country – Indonesia and China holds the largest share by Population

The report studies the market/screened population of Eight big Asian countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) which provides a complete country-wise analysis of Asia Cervical Cancer Screening Market.

All the 8 Asian countries in the report have been studied from 3 viewpoints.

Cervical Cancer Diagnostic Market
  • Pap Smear Tests Market
  • HPV DNA Tests Market
  • VIA Tests Market
Cervical Cancer Test Population
  • Pap Smear Test Population
  • HPV DNA Test Population
  • VIA Test Population
Cervical Cancer Mortality Population
  • Japan
  • Korea
All the 8 Countries Studied in the Report are as Follows
  • Japan
  • Korea
  • Singapore
  • Malaysia
  • India
  • China
  • Thailand
  • Indonesia
1. EXECUTIVE SUMMARY

2. ASIA CERVICAL CANCER TEST (SCREENING) ANALYSIS

2.1 Asia Cervical Cancer Test Population
  2.1.1 Pap smear Test Population
  2.1.2 HPV DNA Test Population
  2.1.3 VIA Test Population
2.2 Asia Cervical Cancer Test (Screening) Market
  2.2.1 Pap Smear Test Market
  2.2.2 HPV DNA Test Market
  2.2.3 Visual Inspection with Acetic Acid (VIA) Test Market

3. MARKET & POPULATION SHARE – BY COUNTRIES

3.1 Asia Cervical Cancer Test Population
  3.1.1 Pap Smear Population
  3.1.2 HPV DNA Population
  3.1.3 VIA Population
3.2 As Market Share – By Countries
  3.2.1 Pap Smear Market
  3.2.2 HPV DNA Market
  3.2.3 VIA Market

4. JAPAN – CERVICAL CANCER TEST ANALYSIS

4.1 Population - Cervical Cancer Test (Screening)
  4.1.1 Pap smear Test Population
  4.1.2 HPV DNA Test Population
4.2 Japan Cervical Cancer Mortality
4.3 Market – Cervical Cancer Test (Screening)
  4.3.1 Pap Smear Test Market
  4.3.2 HPV DNA Test Market

5. SOUTH KOREA – CERVICAL CANCER TESTS ANALYSIS

5.1 Population – Cervical Cancer Test (Screening)
  5.1.1 Pap Smear Test Population
  5.1.2 HPV DNA Test Population
5.2 Korea Cervical Cancer Mortality
5.3 Market – Cervical Cancer Test (Screening)
  5.3.1 Pap Smear Test Market
  5.3.2 HPV DNA Test Market

6. SINGAPORE – CERVICAL CANCER TESTS ANALYSIS

6.1 Population – Cervical Cancer Test (Screening)
  6.1.1 Pap Smear Test Population
  6.1.2 HPV DNA Test Population
6.2 Market – Cervical Cancer Test (Screening)
  6.2.1 Pap Smear Test Market
  6.2.2 HPV DNA Test Market

7. MALAYSIA – CERVICAL CANCER TEST ANALYSIS

7.1 Population – Cervical Cancer Test (Screening)
  7.1.1 Pap Smear Test Population
  7.1.2 HPV DNA Test Population
7.2 Market – Cervical Cancer Test (Screening)
  7.2.1 Pap Smear Test Market
  7.2.2 HPV DNA Test Market

8. INDIA – CERVICAL CANCER TEST ANALYSIS

8.1 Population – Cervical Cancer Test (Screening)
  8.1.1 Pap Smear Test Population
  8.1.2 HPV DNA Test Population
  8.1.3 VIA Test Population
8.2 Market – Cervical Cancer Test (Screening)
  8.2.1 Pap Smear Test Market
  8.2.2 HPV DNA Test Market
  8.2.3 VIA Test Market

9. CHINA – CERVICAL CANCER TEST ANALYSIS

9.1 Population – Cervical Cancer Test (Screening)
  9.1.1 Pap Smear Test Population
  9.1.2 HPV DNA Test Population
  9.1.3 VIA Test Population
9.2 Market – Cervical Cancer Test (Screening)
  9.2.1 Pap Smear Test Population
  9.2.2 HPV DNA Test Population
  9.2.3 VIA Test Market

10. THAILAND – CERVICAL CANCER TEST ANALYSIS

10.1 Population – Cervical Cancer Test (Screening)
  10.1.1 Pap Smear Test Population
  10.1.2 VIA Test Population
10.2 Market – Cervical Cancer Test (Screening)
  10.2.1 Pap Smear Test Market
  10.2.2 VIA Test Market

11. INDONESIA – CERVICAL CANCER TEST ANALYSIS

11.1 Population – Cervical Cancer Test (Screening)
  11.1.1 Pap Smear Test Population
  11.1.2 HPV DNA Test Population
  11.1.3 VIA Test Population
  11.1.4 Pap smear & VIA Test Population
11.2 Market – Cervical Cancer Test (Screening)
  11.2.1 Pap smear Test Market
  11.2.2 HPV DNA Test Market
  11.2.3 VIA Test Market
  11.2.4 Pap smear & VIA Test Market

12. GROWTH DRIVERS

12.1 Introduction of Low Cost VIA Test
  12.1.1 Countries Offering VIA Test via National Programs
  12.1.2 Countries Offering VIA Test via Pilot Programs
12.2 Worldwide Rising Incidence of Teenage Sexual Cases
12.3 Worldwide High Prevalence of HPV Infected Patients

13. CHALLENGES

13.1 Lack of Appropriate Healthcare Infrastructure
13.2 Introduction of HPV Vaccination Programs Worldwide

LIST OF FIGURES:

Figure 2-1: Asia – Cervical Cancer Test Population (Million), 2011 – 2017
Figure 2-2: Asia – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
Figure 2-3: Asia – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
Figure 2-4: Asia – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
Figure 2-5: Asia – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
Figure 2-6: Asia – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
Figure 2-7: Asia – Cervical Cancer VIA Test Population (Million), 2011 – 2017
Figure 2-8: Asia – Forecast for Cervical Cancer VIA Test Population (Million), 2018 – 2024
Figure 2-9: Asia – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 2-10: Asia – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 2-11: Asia – Cervical Cancer Pap smear Test Market (Million US$), 2011 – 2017
Figure 2-12: Asia – Forecast for Cervical Cancer Pap smear Test Market (Million US$), 2018 – 2024
Figure 2-13: Asia – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
Figure 2-14: Asia – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024
Figure 2-15: Asia – Cervical Cancer VIA Test Market (Million US$), 2011 – 2017
Figure 2-16: Asia – Forecast for Cervical Cancer VIA Test Market (Million US$), 2018 – 2024
Figure 3-1: Asia – Cervical Cancer Test Population Share (%), 2011 – 2017
Figure 3-2: Asia – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
Figure 3-3: Asia – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
Figure 3-4: Asia – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
Figure 3-5: Asia – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
Figure 3-6: Asia – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
Figure 3-7: Asia – Cervical Cancer VIA Test Population Share (%), 2011 – 2017
Figure 3-8: Asia – Forecast for Cervical Cancer VIA Test Population Share (%), 2018 – 2024
Figure 3-9: Asia – Cervical Cancer Test Market Share (%), 2011 – 2017
Figure 3-10: Asia – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
Figure 3-11: Asia – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
Figure 3-12: Asia – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
Figure 3-13: Asia – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
Figure 3-14: Asia – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024
Figure 3-15: Asia – cervical cancer VIA Test Market Share (%), 2011 – 2017
Figure 3-16: Asia – Forecast for cervical cancer VIA Test Market Share (%), 2018 – 2024
Figure 4-1: Japan – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 4-2: Japan – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 4-3: Japan – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 4-4: Japan – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 4-5: Japan – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 4-6: Japan – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 4-7: Japan – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 4-8: Japan – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 4-9: Japan – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 4-10: Japan – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 4-11: Japan – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 4-12: Japan – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 4-13: Japan – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 5-1: Korea – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 5-2: Korea – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 5-3: Korea – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 5-4: Korea – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 5-5: Korea – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 5-6: Korea – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 5-7: Korea – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 5-8: Korea – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 5-9: Korea – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 5-10: Korea – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 5-11: Korea – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 5-12: Korea – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 5-13: Korea – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 6-1: Singapore – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 6-2: Singapore – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 6-3: Singapore – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 6-4: Singapore – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 6-5: Singapore – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 6-6: Singapore – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 6-7: Singapore – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 6-8: Singapore – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 6-9: Singapore – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 6-10: Singapore – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 6-11: Singapore – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 6-12: Singapore – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 7-1: Malaysia – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 7-2: Malaysia – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 7-3: Malaysia – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 7-4: Malaysia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 7-5: Malaysia – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 7-6: Malaysia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 7-7: Malaysia – Cervical Cancer Test Market (Million US$), 2011– 2017
Figure 7-8: Malaysia – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 7-9: Malaysia – Pap smear Test Market (Million US$), 2011 – 2017
Figure 7-10: Malaysia – Forecast for Pap smear Test Market (Million US$), 2018 – 2024
Figure 7-11: Malaysia – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 7-12: Malaysia – Forecast for HPV DNA Test Market (Million US$), 2018– 2024
Figure 8-1: India – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 8-2: India – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 8-3: India – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 8-4: India – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 8-5: India – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 8-6: India – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 8-7: India – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017
Figure 8-8: India – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024
Figure 8-9: India – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 8-10: India – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 8-11: India – Pap smear Test Market (Million US$), 2011 – 2017
Figure 8-12: India – Forecast for Pap smear Test Market (Million US$), 2018 – 2024
Figure 8-13: India – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 8-14: India – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 8-15: India – VIA Test Market (Million US$), 2011 – 2017
Figure 8-16: India – Forecast for VIA Test Market (Million US$), 2018 – 2024
Figure 9-1: China – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 9-2: China – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 9-3: China – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 9-4: China – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 9-5: China – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 9-6: China – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 9-7: China – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017
Figure 9-8: China – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024
Figure 9-9: China – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 9-10: China – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 9-11: China – Pap smear Test Market (Million US$), 2011 – 2017
Figure 9-12: China – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 9-13: China – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 9-14: China – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 9-15: China – VIA Test Market (Million US$), 2011 – 2017
Figure 9-16: China – Forecast for VIA Test Market (Million US$), 2018 – 2024
Figure 10-1: Thailand – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 10-2: Thailand – Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 10-3: Thailand – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 10-4: Thailand – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 10-5: Thailand – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017
Figure 10-6: Thailand – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024
Figure 10-7: Thailand – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 10-8: Thailand – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 10-9: Thailand – Pap smear Test Market (Million US$), 2011 – 2017
Figure 10-10: Thailand – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 10-11: Thailand – VIA Test Market (Million US$), 2011 – 2017
Figure 10-12: Thailand – Forecast for VIA Test Market (Million US$), 2018 – 2024
Figure 11-1: Indonesia – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 11-2: Indonesia – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 11-3: Indonesia – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 11-4: Indonesia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 11-5: Indonesia – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 11-6: Indonesia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 11-7: Indonesia – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017
Figure 11-8: Indonesia – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024
Figure 11-9: Indonesia – Cervical Cancer Both (Pap smear & VIA) Test Population (Thousand), 2011 – 2017
Figure 11-10: Indonesia – Forecast for Cervical Cancer Both (Pap smear & VIA) Test Population (Thousand), 2018 – 2024
Figure 11-11: Indonesia – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 11-12: Indonesia – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 11-13: Indonesia – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 11-14: Indonesia – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 11-15: Indonesia – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 11-16: Indonesia – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 11-17: Indonesia – VIA Test Market (Million US$), 2011 – 2017
Figure 11-18: Indonesia – Forecast for VIA Test Market (Million US$), 2018 – 2024
Figure 11-19: Indonesia – Both (Pap smear & VIA) Test Market (Million US$), 2011 – 2017
Figure 11-20: Indonesia – Forecast for Both (Pap smear & VIA) Test Market (Million US$), 2018 – 2024

LIST OF TABLES:

Table 12 1: Worldwide – List of Countries which offer VIA Test via National Programs, 2015
Table 12 2: Worldwide – List of Countries which offer VIA Test via Pilot Programs, 2015
Table 12 3: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006
Table 12 4: Worldwide – Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014 - 2015


More Publications